MCID: NNS003
MIFTS: 32

Non-Secretory Myeloma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Non-Secretory Myeloma

MalaCards integrated aliases for Non-Secretory Myeloma:

Name: Non-Secretory Myeloma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9547
UMLS 73 C0456845

Summaries for Non-Secretory Myeloma

MalaCards based summary : Non-Secretory Myeloma is related to myeloma, multiple and indolent myeloma. An important gene associated with Non-Secretory Myeloma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins and ECM-receptor interaction. The drugs Dexamethasone and Pomalidomide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and kidney, and related phenotype is neoplasm.

Related Diseases for Non-Secretory Myeloma

Diseases related to Non-Secretory Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 myeloma, multiple 29.2 ALB B2M CD19 CD38 FN1 MYOM2
2 indolent myeloma 10.2 B2M MYOM2
3 extramedullary plasmacytoma 10.2 B2M MYOM2
4 amyloid tumor 10.2 B2M MYOM2
5 prostate squamous cell carcinoma 10.2 B2M SMUG1
6 commensal bacterial infectious disease 10.2 MYOM2 SETBP1
7 cecum adenocarcinoma 10.2 B2M SMUG1
8 uterine corpus sarcoma 10.2 CD38 SMUG1
9 hypersensitivity reaction type iv disease 10.2 MYOM2 SMUG1
10 immunodeficiency 43 10.1 ALB B2M
11 orthostatic proteinuria 10.1 ALB B2M
12 diffuse glomerulonephritis 10.1 ALB B2M
13 danubian endemic familial nephropathy 10.1 ALB B2M
14 gastrointestinal tuberculosis 10.1 ALB SMUG1
15 hepatic tuberculosis 10.1 ALB SMUG1
16 hemorrhagic fever 10.1 ALB B2M
17 klatskin's tumor 10.1 ALB SMUG1
18 acute kidney tubular necrosis 10.1 ALB B2M
19 tuberculous peritonitis 10.1 ALB SMUG1
20 pericardium disease 10.1 ALB SMUG1
21 xanthogranulomatous pyelonephritis 10.1 ITGAX SMUG1
22 anterior scleritis 10.1 B2M CD19
23 bone marrow cancer 10.1 B2M CD38 MYOM2
24 meningoencephalitis 10.1 ALB B2M
25 b-cell expansion with nfkb and t-cell anergy 10.1 B2M CD38
26 hemorrhagic fever with renal syndrome 10.1 ALB B2M
27 pleural disease 10.1 ALB SMUG1
28 invasive malignant thymoma 10.0 CD19 CD38
29 lung lymphoma 10.0 CD19 SMUG1
30 b cell prolymphocytic leukemia 10.0 CD19 CD38
31 prolymphocytic leukemia 10.0 CD19 CD38
32 lymphatic system cancer 10.0 CD19 SMUG1
33 gamma heavy chain disease 10.0 CD19 CD38
34 arcus corneae 10.0 ALB FN1
35 bladder lymphoma 10.0 CD19 ITGAX
36 small intestine lymphoma 10.0 B2M CD19 ITGAE
37 acquired immunodeficiency syndrome 10.0 ALB B2M CD38
38 intestinal disease 10.0 ALB DDX53 SMUG1
39 gastrointestinal system cancer 10.0 ALB DDX53 SMUG1
40 gastrointestinal system disease 10.0 ALB DDX53 SMUG1
41 esophageal disease 10.0 ALB SMUG1
42 lymphoma, hodgkin, classic 10.0 CD19 SMUG1
43 plasma protein metabolism disease 10.0 CD19 CD38 MYOM2
44 acute kidney failure 10.0 ALB B2M
45 myelodysplastic syndrome 9.9
46 disseminated intravascular coagulation 9.9
47 relapsing polychondritis 9.9
48 amyloidosis 9.9
49 polymyositis 9.9
50 pleuropneumonia 9.9 CD19 CXCL9

Graphical network of the top 20 diseases related to Non-Secretory Myeloma:



Diseases related to Non-Secretory Myeloma

Symptoms & Phenotypes for Non-Secretory Myeloma

MGI Mouse Phenotypes related to Non-Secretory Myeloma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 ALB B2M CD19 FN1 SMUG1

Drugs & Therapeutics for Non-Secretory Myeloma

Drugs for Non-Secretory Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
2 Pomalidomide Approved Phase 3,Phase 2 19171-19-8
3
Lenalidomide Approved Phase 3 191732-72-6 216326
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
5
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
6 interferons Phase 3
7 Gastrointestinal Agents Phase 3,Phase 2
8
protease inhibitors Phase 3,Phase 2,Phase 1
9 Antineoplastic Agents, Hormonal Phase 3,Phase 2
10 Angiogenesis Modulating Agents Phase 3,Phase 2
11 Autonomic Agents Phase 3,Phase 2
12 Angiogenesis Inhibitors Phase 3,Phase 2
13 Antiemetics Phase 3,Phase 2
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
15 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
16 Immunologic Factors Phase 3,Phase 2
17 Anti-Inflammatory Agents Phase 3,Phase 2
18 glucocorticoids Phase 3,Phase 2
19 Peripheral Nervous System Agents Phase 3,Phase 2
20 BB 1101 Phase 3,Phase 2
21 Hormones Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 3,Phase 2
23 Hormone Antagonists Phase 3,Phase 2
24 Anti-Infective Agents Phase 3,Phase 2
25 Immunosuppressive Agents Phase 3,Phase 2
26
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
27
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
28
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
29
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
30
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
31
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33 Histone Deacetylase Inhibitors Phase 2
34 Antineoplastic Agents, Alkylating Phase 2
35 Alkylating Agents Phase 2
36 Antirheumatic Agents Phase 2
37 Vaccines Phase 2
38 Protective Agents Phase 2
39 Bendamustine Hydrochloride Phase 2
40 Methylprednisolone acetate Phase 2
41 Prednisolone acetate Phase 2
42 Neuroprotective Agents Phase 2
43
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
44
Sorafenib Approved, Investigational Phase 1 284461-73-0 216239 406563
45 Ixazomib Approved, Investigational Phase 1 1072833-77-2
46
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
48
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
49
Citric Acid Approved, Nutraceutical, Vet_approved Phase 1 77-92-9 311
50 Micronutrients Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) Completed NCT00732641 Phase 3 Peginterferon
2 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study Completed NCT01311687 Phase 3 pomalidomide;Dexamethasone
3 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Completed NCT01324947 Phase 3 pomalidomide
4 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 2 panobinostat;bortezomib;dexamethasone
5 Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma Completed NCT02011113 Phase 2 Pomalidomide;Dexamethasone
6 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Completed NCT01094548 Phase 2 Single low dose cyclophosphamide;Multiple low dose cyclophosphamide
7 Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma Completed NCT01849848 Phase 2 SyB L-0501
8 Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma Terminated NCT01179490 Phase 2 SyB L-0501;prednisolone
9 Sorafenib and Bortezomib in Treating Patients With Advanced Cancer Completed NCT00303797 Phase 1 17-N-allylamino-17-demethoxygeldanamycin/bortezomib;sorafenib tosylate
10 Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma Completed NCT00963820 Phase 1 Ixazomib citrate

Search NIH Clinical Center for Non-Secretory Myeloma

Genetic Tests for Non-Secretory Myeloma

Anatomical Context for Non-Secretory Myeloma

MalaCards organs/tissues related to Non-Secretory Myeloma:

41
Bone, Lung, Kidney, Prostate, B Cells, Bone Marrow, Small Intestine

Publications for Non-Secretory Myeloma

Articles related to Non-Secretory Myeloma:

(show all 16)
# Title Authors Year
1
Non-Secretory Myeloma: Ready for a new Definition? ( 28894562 )
2017
2
Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy. ( 27504298 )
2016
3
A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions. ( 26003102 )
2015
4
Non-secretory myeloma: clinical and biologic implications. ( 24282995 )
2013
5
Non-secretory myeloma: one, two, or more entities? ( 24282994 )
2013
6
Non-secretory myeloma: a clinician's guide. ( 24282993 )
2013
7
Polymyositis associated with non-secretory myeloma - a case report. ( 23393512 )
2011
8
Non-secretory myeloma: a rare variant of multiple myeloma. ( 18803898 )
2008
9
Relapsing polychondritis, smouldering non-secretory myeloma and early myelodysplastic syndrome in the same patient: three difficult diagnoses produce a life threatening illness. ( 10634653 )
2000
10
Twelve-year profile of a non-secretory myeloma with amyloidosis. ( 2282322 )
1990
11
Skin involvement in non-secretory myeloma. ( 3407670 )
1988
12
Hypercalcaemia in a patient with non-secretory myeloma. ( 3211820 )
1988
13
Non-secretory myeloma. ( 3793705 )
1986
14
Demonstration of serum monoclonal immunoglobulin in a case of non-secretory myeloma by immunoisoelectric focusing. ( 3926829 )
1985
15
Disseminated intravascular coagulation in a case of non-secretory myeloma. ( 6511287 )
1984
16
Intact and fragmented intracellular immunoglobulin in a case of non-secretory myeloma. ( 1123437 )
1975

Variations for Non-Secretory Myeloma

Expression for Non-Secretory Myeloma

Search GEO for disease gene expression data for Non-Secretory Myeloma.

Pathways for Non-Secretory Myeloma

GO Terms for Non-Secretory Myeloma

Cellular components related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 B2M CD19 CXCL9 ITGAE ITGAX
2 integrin complex GO:0008305 8.96 ITGAE ITGAX

Biological processes related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.33 ALB B2M FN1
2 retina homeostasis GO:0001895 9.26 ALB B2M
3 extracellular matrix organization GO:0030198 9.13 FN1 ITGAE ITGAX
4 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 8.62 CD19 CXCL9

Sources for Non-Secretory Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....